Small molecule innovator and generic active pharmaceutical ingredient (API) manufacturer Cambrex is acquiring dosage form contract development and manufacturing organization (CDMO) Halo Pharma for approximately $425 million. With the acquisition of Halo, Cambrex will enter the large and growing finished dosage form CDMO market. Halo provides drug product development and commercial manufacturing services, specializing in oral solids, liquids, creams, sterile and non-sterile ointments. Halo’...